Last reviewed · How we verify
TTP399
At a glance
| Generic name | TTP399 |
|---|---|
| Sponsor | vTv Therapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes (PHASE3)
- Evaluation of TTP399 in Patients With Type 1 Diabetes (PHASE1, PHASE2)
- Add Glucokinase Activator to Target A1c (PHASE2)
- A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TTP399 CI brief — competitive landscape report
- TTP399 updates RSS · CI watch RSS
- vTv Therapeutics portfolio CI